title: The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy.
abstract: To assess the prognostic value of preoperative C-reactive protein (CRP) serum levels for prognostication of biochemical recurrence (BCR) after radical prostatectomy (RP) in a large multi-institutional cohort.
  
  
  
  Data from 7205 patients treated with RP at five institutions for clinically localized prostate cancer (PCa) were retrospectively analyzed. Preoperative serum levels of CRP within 24 h before surgery were evaluated. A CRP level ⩾0.5 mg dl(-1) was considered elevated. Associations of elevated CRP with BCR were evaluated using univariable and multivariable Cox proportional hazards regression models. Harrel's C-index was used to assess prognostic accuracy (PA).
  
  
  
  Patients with higher Gleason score on biopsy and RP, extracapsular extension, seminal vesicle invasion, lymph node metastasis, and positive surgical margins status had a significantly elevated preoperative CRP compared to those without these features. Patients with elevated CRP had a lower 5-year BCR survival proportion as compared to those with normal CRP (55% vs 76%, respectively, P<0.0001). In pre- and postoperative multivariable models that adjusted for standard clinical and pathologic features, elevated CRP was independently associated with BCR (P<0.001). However, the addition of preoperative CRP did not improve the accuracy of the standard pre- and postoperative models for prediction of BCR (70.9% vs 71% and 78.9% vs 78.7%, respectively).
  
  
  
  Preoperative CRP is elevated in patients with pathological features of aggressive PCa and BCR after RP. While CRP has independent prognostic value, it does not add prognostically or clinically significant information to standard predictors of outcomes.
authors.affiliation: Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Sevcenco
authors.affiliation: Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.|Department of Urology, Rennes University Hospital, Rennes, France.
authors.forename: R
authors.initials: R
authors.lastname: Mathieu
authors.affiliation: Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Baltzer
authors.affiliation: Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.
authors.forename: T
authors.initials: T
authors.lastname: Klatte
authors.affiliation: Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Fajkovic
authors.affiliation: Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Seitz
authors.affiliation: Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
authors.forename: P I
authors.initials: PI
authors.lastname: Karakiewicz
authors.affiliation: Academic Department of Urology, La Pitié-Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Rouprêt
authors.affiliation: Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Rink
authors.affiliation: Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Kluth
authors.affiliation: School of Medicine, Sacramento, CA, USA.|Department of Surgery, Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: Q-D
authors.initials: QD
authors.lastname: Trinh
authors.affiliation: Department of Urology, Krankenhaus der Barmherzigen Schwestern, Linz, Austria.
authors.forename: W
authors.initials: W
authors.lastname: Loidl
authors.affiliation: Urological Research Institute, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Briganti
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York, NY, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Scherr
authors.affiliation: Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria.|Department of Urology, Weill Cornell Medical College, New York, NY, USA.|Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
authors.forename: S F
authors.initials: SF
authors.lastname: Shariat
mesh_terms: D000368:Aged; D002097:C-Reactive Protein; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D057234:Preoperative Period; D011379:Prognosis; D016016:Proportional Hazards Models; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery; D012008:Recurrence
chemical_list: D002097:C-Reactive Protein
references.citation: BJU Int. 2011 Dec;108(11):1800-5
references.pmid: 21507193
references.citation: Eur Urol. 2007 Dec;52(6):1601-9
references.pmid: 17919807
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3785-91
references.pmid: 18559597
references.citation: BJU Int. 2013 Jun;111(8):E348-53
references.pmid: 23495750
references.citation: Prostate Cancer Prostatic Dis. 2008;11(2):112-20
references.pmid: 17998918
references.citation: Cancer. 2013 Sep 15;119(18):3272-9
references.pmid: 23818401
references.citation: Urol Oncol. 2012 Jan-Feb;30(1):33-7
references.pmid: 20207556
references.citation: Asian J Androl. 2014 May-Jun;16(3):467-71
references.pmid: 24589465
references.citation: Tumour Biol. 2015 Feb;36(2):669-73
references.pmid: 25286759
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1223-31
references.pmid: 12663708
references.citation: BJU Int. 2012 Dec;110(11 Pt B):E461-8
references.pmid: 22520631
references.citation: Urol Int. 2010;84(4):430-5
references.pmid: 20395655
references.citation: Eur Urol. 2011 Jan;59(1):88-95
references.pmid: 20965646
references.citation: Prostate. 2007 May 1;67(6):614-22
references.pmid: 17299799
references.citation: Clin Genitourin Cancer. 2015 Aug;13(4):e217-21
references.pmid: 25735198
references.citation: Eur J Cancer. 2015 Mar;51(5):610-9
references.pmid: 25618827
references.citation: Nat Rev Urol. 2011 Oct 25;8(12):659-66
references.pmid: 22025173
references.citation: Urology. 2011 Nov;78(5):1131-5
references.pmid: 22054387
references.citation: J Clin Invest. 2003 Jun;111(12):1805-12
references.pmid: 12813013
references.citation: Kidney Int. 2005 Nov;68(5):2103-10
references.pmid: 16221209
references.citation: CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
references.pmid: 25559415
references.citation: Urol Oncol. 2014 Jan;32(1):50.e1-8
references.pmid: 24239465
references.citation: J Natl Cancer Inst. 2006 May 17;98(10):715-7
references.pmid: 16705126
references.citation: Eur Urol. 2010 Nov;58(5):687-700
references.pmid: 20727668
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7005-12
references.pmid: 16192588
references.citation: Clin Cancer Res. 2004 Mar 15;10(6):1992-9
references.pmid: 15041717
references.citation: Immunol Res. 2001;24(2):163-76
references.pmid: 11594454
references.citation: Cancer. 2008 Dec 1;113(11):3075-99
references.pmid: 18823041